Navigation Links
BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
Date:7/23/2008

INDIANAPOLIS, July 23 /PRNewswire/ -- BioStorage Technologies, Inc. (BST) will serve as the biorepository partner for the first phase of the Indiana Health Study, a new landmark longitudinal study of coronary artery disease. This community-based research initiative will utilize the population of Indianapolis and surrounding areas as study participants and will enable research that will lead to new drugs and diagnostics that allow doctors to better manage common, chronic diseases such as heart disease, cancer and diabetes.

Sponsored by the Fairbanks Institute for Healthy Communities, an Indianapolis-based nonprofit organization, the Indiana Health Study will create one of the nation's most comprehensive resources for academic and commercial research by integrating biological samples, medical data and lifestyle information collected from two cohorts of people: patients with coronary artery disease and people without the disease.

The collected biological samples will be stored at BST's state-of-the-art facility located in Indianapolis. "We selected BioStorage because of their expertise in cold chain logistics, sample management and long term storage, which are all necessities for a study of this scope and importance," said Dr. Cynthia Helphingstine, president and COO of the Fairbanks Institute. "We are fortunate to have partnered with a company that shares our strong commitment for community-based life science research."

Dr. John F. Mills, M.D., Ph.D., chief executive officer of BioStorage Technologies believes the Indiana Health Study can make a significant impact on the future of health care for people in Indiana and around the world. "We believe we can play a vital role in advancing health care and research initiatives through ensuring sample integrity. In a study of this magnitude samples are vital and could possibly hold the key to unlocking the causes of some of this nation's deadliest diseases."

While the Indiana Health Study will follow participants for years, Helphingstine anticipates immediate benefits as well. Samples will be available for researchers as soon as they are collected. The Fairbanks Institute intends to study multiple chronic diseases with future research platforms including studies on cancer, diabetes and central nervous system disorders.

About BioStorage Technologies, Inc.:

BioStorage Technologies, Inc. is a leader in sample storage, inventory management and coldchain logistics for the biotechnology and pharmaceutical industries. The company offers secure, temperature-controlled storage; real-time tracking of stored biological samples; and next-day return of biomaterials. BioStorage Technologies is privately-held and headquartered in Indianapolis with an additional full-service site near Frankfurt, Germany. For more information, visit http://www.biostorage.com or call +1 (866) 697-2675 or +49-6155-898-1010.

About Fairbanks Institute

Formed with a $10 million gift from the Richard M. Fairbanks Foundation and the collaboration of BioCrossroads, Indiana University School of Medicine, Regenstrief Institute and other Indianapolis community health leaders, Fairbanks Institute is creating one of the nation's most comprehensive resources for finding better ways to prevent, diagnose and treat the nation's most common, chronic diseases.

Press Contact:

Whitney Dean

Miller Brooks, Inc.

317-873-8100

whitney@millerbrooks.com


'/>"/>
SOURCE BioStorage Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008
2. BioStorage Technologies Forms Scientific Advisory Board with Leading Life Science Experts
3. BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations
4. BioStorage Technologies Appoints Lori Ball as Vice President
5. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
6. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
7. MacroGenics Acquires Raven Biotechnologies
8. Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing and the Importance of New Medicare-Related E-Prescribing Legislation
9. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
10. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
11. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on ... that it will present at the 18 th ... 8, 2016 at 10:00 a.m. EST in New ... DelMar,s president and CEO, will provide an update on the ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/4/2016)... Strasbourg, France , to the US ... Strasbourg, France , to the US company Advanced Bioscience ... announce that it acted as an advisor to Transgene on ... Strasbourg, France , to the US company Advanced Bioscience ... Transgene (Euronext: TNG), a member of Institut Mérieux, is ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
Breaking Biology Technology:
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 /PRNewswire/ ... sensor-based diagnostic products, today announced the closing of a $9 ... investors.  Proceeds from the financing will be used to accelerate ... device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has been ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
(Date:1/6/2016)... Jan. 6, 2016 Based on its ... & Sullivan recognizes MorphoTrak, LLC, a U.S. subsidiary ... Frost & Sullivan Company of the Year Award. ... technology, Morpho Wave™ , has consolidated the company,s ... biometrics market. Morpho Wave is a highly ...
Breaking Biology News(10 mins):